NCI seeks proposals from parties interested in licensing an improved method for the identification of TCRs from bulk populations of TIL for the development of cancer immunotherapies.
This technology describes additional methods of using the griffithsin anti-viral polypeptides described in related NCI invention (reference number E-106-2003). Specifically, this invention describes the use of GRFT to inhibit viral infection of hepatitis C viral infection, a severe acute respiratory syndrome (SARS) viral infection, an H5N1 viral infection, or an Ebola viral infection.
Researchers at the NCI seek research and co-development partners and/or licensing for the development of human monoclonal antibodies and antibody-based therapeutics against CD22.
Inventors are seeking licensing and/or co-development research collaborations for a unique novel molecular Adjuvanted Mucosal Subunit Vaccine to prevent SARS-CoV-2 transmission and infection.
NCI is seeking licensees for the AT-3 mouse breast tumor cell line.
The NIA seeks co-development partners and/or licensees for the further development of Cα-peptide as a therapeutic that inhibits islet amyloidosis.
The NICHD is seeking licensees for development of Carboxypeptidase E (CPE) as a therapy for MCI or AD.
NICHD is seeking research co-development partners and/or licensees for development of this invention as a male contraceptive.
NICHD is seeking licensees for development of an adeno-associated viral (AAV) vectors for the treatment of glycogen storage disease type Ia (GSD-Ia).
Primary mediastinal B-cell lymphoma (PMBCL) is an aggressive type of non-Hodgkin lymphoma that mostly occurs in people between the ages of 30-40. It accounts for 5-7% of all aggressive lymphomas. The diagnosis of PMBCL is challenging as the histological features of PMBCL overlap with diffuse large B-cell lymphoma (DLBCL), another most common type of non-Hodgkin lymphoma. Available evidence suggests that PMBCL responds much more favorably to the DA-EPOCH-R chemotherapy regimen than to the standard R-CHOP regimen used to treat DLBCL.